Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20228114 | 1.00 | MT-CO2 (0.33) | MT-CO2ALOX5POLBCYP2D6MAPK1 | |
| SCHEMBL19703674 | 0.83 | MT-CO2 (0.31) | MT-CO2ALOX5POLBCYP2D6MAPK1 | |
| SCHEMBL20798888 | 0.83 | MT-CO2 (0.31) | MT-CO2ALOX5POLBCYP2D6MAPK1 | |
| SCHEMBL20215129 | 0.83 | MT-CO2 (0.31) | MT-CO2ALOX5 | |
| SCHEMBL21152792 | 0.83 | MT-CO2 (0.31) | MT-CO2ALOX5POLBCYP2D6MAPK1 | |
| SCHEMBL23839856 | 0.83 | MT-CO2 (0.31) | MT-CO2ALOX5 | |
| SCHEMBL22472732 | 0.82 | PIK3CD (0.34) | MT-CO2ALOX5 | |
| SCHEMBL25070877 | 0.80 | — | — | |
| SCHEMBL21162932 | 0.79 | — | — | |
| SCHEMBL19134327 | 0.79 | ALDH1A1 (0.30) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240016949-A1 | ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240016949-A1 | ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11857635-B2 | Linker compound, polyethylene glycol-linker conjugate and derivative thereof and polyethylene glycol-linker-drug conjugate | JENKEM TECHNOLOGY CO., LTD. (TIANJIN) (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11857635-B2 | Linker compound, polyethylene glycol-linker conjugate and derivative thereof and polyethylene glycol-linker-drug conjugate | JENKEM TECHNOLOGY CO., LTD. (TIANJIN) (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-11806405-B1 | Immunoconjugates and methods | ZENO MANAGEMENT, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4265274-A1 | B7-H3 TARGETING ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230330242-A1 | IMMUNOCONJUGATES AND METHODS | IMMUNOME, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20140065171-A1 | Site-Specific Labeling Methods and Molecules Produced Thereby | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-03-06 | — | — | US | disclosed |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | BYONDIS B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| US-20130137645-A1 | MODIFIED PEPTIDES AND PROTEINS | AmideBio LLC | 2013-05-30 | — | — | US | disclosed |
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | SYNTARGA B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090246211-A1 | Molecular constructs suitable for targeted conjugates | TAPESTRY PHARMACEUTICALS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090246211-A1 | Molecular constructs suitable for targeted conjugates | TAPESTRY PHARMACEUTICALS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | MT-CO2 4797/4885ALOX5 1062/4885POLB 73/4885 |
| US-20130137645-A1 | MODIFIED PEPTIDES AND PROTEINS | IAPP, VIP, ENPEP | MT-CO2 4474/4885ALOX5 4079/4885POLB 3694/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | MT-CO2 4689/4885ALOX5 1414/4885POLB 3279/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | MT-CO2 3611/4885ALOX5 3643/4885POLB 3180/4885 |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | PCNA, CDC5L, TOP1 | MT-CO2 4590/4885ALOX5 1527/4885POLB 221/4885 |
| US-11806405-B1 | Immunoconjugates and methods | CD4, L1CAM, PDCD1LG2 | MT-CO2 3040/4885ALOX5 3632/4885POLB 3682/4885 |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | PCNA, TOP1, TOP2B | MT-CO2 4376/4885ALOX5 1105/4885POLB 170/4885 |
| US-20090246211-A1 | Molecular constructs suitable for targeted conjugates | MRPL21, QSOX1, MLX | MT-CO2 3331/4885ALOX5 3909/4885POLB 3551/4885 |
| US-20230330242-A1 | IMMUNOCONJUGATES AND METHODS | CD4, L1CAM, PDCD1LG2 | MT-CO2 3040/4885ALOX5 3632/4885POLB 3682/4885 |
| US-11857635-B2 | Linker compound, polyethylene glycol-linker conjugate and derivative thereof and polyethylene glycol-linker-drug conjugate | DCLRE1A, LANCL2, SI | MT-CO2 4514/4885ALOX5 682/4885POLB 2727/4885 |
| US-20240016949-A1 | ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | VSIG8, CD81, WEE1 | MT-CO2 3220/4885ALOX5 4108/4885POLB 4671/4885 |
| US-20140065171-A1 | Site-Specific Labeling Methods and Molecules Produced Thereby | PTMS, DNPEP, PSAT1 | MT-CO2 3687/4885ALOX5 3852/4885POLB 1714/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | MT-CO2 4857/4885ALOX5 3884/4885POLB 4749/4885 |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | PCNA, DCLRE1A, CDC5L | MT-CO2 4180/4885ALOX5 1661/4885POLB 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.